Oppenheimer analyst Jay Olson notes that the FDA has accepted TherapeuticsMD's TX-004HR NDA as a class 2 resubmission which requires a 6-month review resulting in a May 29, 2018 PDUFA. While the analyst is pleased with FDA's acceptance of the resubmission, he is surprised at the agency's designation as a class 2, which was apparently triggered by the additional endometrial safety data. This data was submitted several months ago, giving the FDA a significant head start to review it, he contends. Olson reiterates an Outperform rating and $10 price target on the shares.